PET studies of neuroendcrine tumors by using Br--bromobenzylguanidine (Br-MBBG)
渡邉 茂樹; 花岡 宏史*; Liang, J. X.*; 飯田 靖彦*; 渡辺 智; 遠藤 啓吾*; 石岡 典子
Watanabe, Shigeki; Hanaoka, Hirofumi*; Liang, J. X.*; Iida, Yasuhiko*; Watanabe, Satoshi; Endo, Keigo*; Ishioka, Noriko
I--Iodobenzylgunanidine (I-MIBG), functional analogue of norepinephrine, has been employed for the therapy of neuroendcrine tumors which express norepinephrine transporter (NET). I-MIBG scintigraphy has been also used for diagnosis of NET positive tumors such as detecting metastasis, investigating suitability and monitoring response to the treatment with I-MIBG. However, I-MIBG scintigraphy has limitation to diagnose small legions due to its lower sensitivity and spatial resolution. Since positron emission tomography (PET) is superior to scintigraphy, positron emitter labeled MIBG has potential to improve diagnostic ability of NET positive neuroendcrine tumors. Then, we have reveal the utility of positron emitter Br labeled m-bromobenzylguanidine (Br-MBBG) as a PET tracer for NET positive tumor.